Positive News SentimentPositive NewsNASDAQ:PMD Psychemedics (PMD) Stock Price, News & Analysis $2.67 -0.05 (-1.84%) (As of 12/12/2024) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Psychemedics Stock (NASDAQ:PMD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Psychemedics alerts:Sign Up Key Stats Today's Range$2.46▼$2.7750-Day Range$2.31▼$3.2152-Week Range$1.63▼$3.93Volume113,600 shsAverage Volume21,197 shsMarket Capitalization$15.73 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewPsychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally. It offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opioids, such as heroin metabolite, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, fentanyl and fentanyl analogs, and alcohol. The company's testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. It offers its services to employers for job applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. The company was incorporated in 1986 and is headquartered in Dallas, Texas.Read More… Psychemedics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks29th Percentile Overall ScorePMD MarketRank™: Psychemedics scored higher than 29% of companies evaluated by MarketBeat, and ranked 814th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Psychemedics. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Psychemedics is -5.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Psychemedics is -5.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPsychemedics has a P/B Ratio of 2.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.25% of the float of Psychemedics has been sold short.Short Interest Ratio / Days to CoverPsychemedics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Psychemedics has recently decreased by 3.26%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPsychemedics does not currently pay a dividend.Dividend GrowthPsychemedics has only been increasing its dividend for 1 years. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.25% of the float of Psychemedics has been sold short.Short Interest Ratio / Days to CoverPsychemedics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Psychemedics has recently decreased by 3.26%, indicating that investor sentiment is improving. News and Social Media3.9 / 5News Sentiment1.96 News SentimentPsychemedics has a news sentiment score of 1.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Psychemedics this week, compared to 0 articles on an average week.Search Interest2 people have searched for PMD on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Psychemedics insiders have bought 384.38% more of their company's stock than they have sold. Specifically, they have bought $3,650,628.00 in company stock and sold $753,664.00 in company stock.Percentage Held by Insiders13.96% of the stock of Psychemedics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 32.07% of the stock of Psychemedics is held by institutions.Read more about Psychemedics' insider trading history. Receive PMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Psychemedics and its competitors with MarketBeat's FREE daily newsletter. Email Address PMD Stock News HeadlinesInsider Buying: Psychemedics Co. (NASDAQ:PMD) Major Shareholder Acquires 60,000 Shares of StockDecember 18, 2024 | insidertrades.comPsychemedics Co. (NASDAQ:PMD) Major Shareholder Purchases $19,355.07 in StockDecember 13, 2024 | insidertrades.comWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.December 24, 2024 | Behind the Markets (Ad)Insider Buying: Psychemedics Co. (NASDAQ:PMD) Director Purchases 1,409,712 Shares of StockDecember 6, 2024 | insidertrades.comPsychemedics announces reverse stock split, forward stock splitDecember 3, 2024 | markets.businessinsider.comPsychemedics Corporation Announces Reverse and Forward Stock SplitDecember 2, 2024 | gurufocus.comPsychemedics Corporation Announces Reverse and Forward Stock SplitDecember 2, 2024 | globenewswire.comPsychemedics reminds stockholders to cast votes for Annual MeetingNovember 19, 2024 | markets.businessinsider.comSee More Headlines PMD Stock Analysis - Frequently Asked Questions How have PMD shares performed this year? Psychemedics' stock was trading at $2.96 at the start of the year. Since then, PMD shares have decreased by 9.8% and is now trading at $2.67. View the best growth stocks for 2024 here. How were Psychemedics' earnings last quarter? Psychemedics Co. (NASDAQ:PMD) announced its earnings results on Tuesday, April, 23rd. The company reported $0.11 earnings per share for the quarter. The business earned $9.82 million during the quarter. Psychemedics had a negative trailing twelve-month return on equity of 49.05% and a negative net margin of 14.59%. How do I buy shares of Psychemedics? Shares of PMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Psychemedics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Psychemedics investors own include Pfizer (PFE), NVIDIA (NVDA), DraftKings (DKNG), UnitedHealth Group (UNH), Canopy Growth (CGC), Advanced Micro Devices (AMD) and McDonald's (MCD). Company Calendar Last Earnings4/23/2019Today12/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:PMD CUSIPN/A CIK806517 Webwww.psychemedics.com Phone(978) 206-8220Fax978-264-9236Employees140Year Founded1985Profitability EPS (Most Recent Fiscal Year)($0.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,150,000.00 Net Margins-14.59% Pretax Margin-14.55% Return on Equity-49.05% Return on Assets-27.26% Debt Debt-to-Equity Ratio0.01 Current Ratio1.59 Quick Ratio1.59 Sales & Book Value Annual Sales$22.10 million Price / Sales0.71 Cash FlowN/A Price / Cash FlowN/A Book Value$1.15 per share Price / Book2.32Miscellaneous Outstanding Shares5,890,000Free Float5,071,000Market Cap$15.73 million OptionableNot Optionable Beta0.65 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for January 2025. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:PMD) was last updated on 12/24/2024 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredA.I. Trading System Helps Some Traders Pocket $1,100 per DAY!What if I told you 60 seconds a day could completely change your life? This AI-powered trading syst...Prosper Trading Academy | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWall St. Icon: “If you wait on this, it will already be too late”If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Psychemedics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Psychemedics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.